All In Biotech

Drug Trial Radar · NCT03601871

The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy

The Efficacy and Safety of Thalidomide in Preventing Multi-cycle, Cisplatin-containing CINV: a Pragmatic Randomized Open-label Clinical Trial

Last checked: Nov 20, 2026Latest source record: Jul 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 880 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

880

Planned (sponsor's estimate)

Start

Jul 12, 2018

Primary completion

Jun 30, 2020

Study completion Dec 30, 2020

Sponsor

Lead sponsor
Yunpeng LiuAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a pragmatic randomized, multi-center, open-label randomized clinical trial, aimed to evaluate efficacy and safety of thalidomide in improving prevention of chemotherapy-induced delayed nausea and vomiting (CINV) in chemotherapy-naive patients after multi-cycle cisplatin-containing highly emetogenic chemotherapy (HEC) .

Conditions

  • Chemotherapy-induced Nausea and Vomiting

Interventions

  • ThalidomideDrug

    Thalidomide (Thalidomide Oral Product)100 mg by mouth twice a day on days 1-5 after chemotherapy .

  • DexamethasoneDrug

    Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4

  • 5-HT3 antagonistsDrug

    Palonosetron 0.25 mg intravenously on day 1; or 1st-generation 5-HT3 antagonists (used as clinal routine) on day 1-3

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. No nausea (self report sclae VAS=0)rate in delayed phase (Days2-7) in the first cycle chemotherapyTime frame: Day 2-7 in the first chemotherapy cycle(each cycle is 21 days)

Locations

29 sites in 1 country. Site status is shown where the registry gives one.

  • Central Hospital of Anshan City

    Anshan, China · Not yet recruiting

  • Benxi Central Hospital

    Benxi, China · Not yet recruiting

  • Chaoyang Central Hospital

    Chaoyang, China · Not yet recruiting

  • Zhongshan Hospital

    Dalian, China · Not yet recruiting

  • Liaohe Oilfield General Hospital

    Panjin, China · Not yet recruiting

  • cancer hospital of Haerbin Medical University

    Haerbin, Heilongjiang, China · Not yet recruiting

  • Siping City Cancer Hospital

    Siping, Jilin, China · Not yet recruiting

  • Anshan Hospital of First Hospital of China Medical University

    Anshan, Liaoning, China · Not yet recruiting

  • Anshan Tumor Hospital

    Anshan, Liaoning, China · Not yet recruiting

  • Central hospital of Dalian

    Dalian, Liaoning, China · Not yet recruiting

  • Second Affiliated Hospital of Dalian Medical University

    Dalian, Liaoning, China · Not yet recruiting

  • The Fifth Hospital of Dalian City

    Dalian, Liaoning, China · Not yet recruiting

  • The First Affiliated Hospital of Dalian Medical University

    Dalian, Liaoning, China · Not yet recruiting

  • Zhuanghe Central Hospital

    Dalian, Liaoning, China · Not yet recruiting

  • Fushun Central Hospital

    Fushun, Liaoning, China · Recruiting

  • General Hospital of Mining Bureau

    Fushun, Liaoning, China · Not yet recruiting

  • Jinzhou Central Hospital

    Jinzhou, Liaoning, China · Not yet recruiting

  • The First Hospital of Liaoning Medical University

    Jinzhou, Liaoning, China · Not yet recruiting

  • Chinese Medicine Hospital of Liaoyang county

    Liaoyang, Liaoning, China · Not yet recruiting

  • Liaoyang Central Hospital

    Liaoyang, Liaoning, China · Not yet recruiting

  • Petrochemical General Hospital of Liaoyang city

    Liaoyang, Liaoning, China · Not yet recruiting

  • Panjin central Hospital

    Panjin, Liaoning, China · Not yet recruiting

  • Chest Hospital of Shenyang City

    Shengyang, Liaoning, China · Not yet recruiting

  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, China · Not yet recruiting

  • General Hospital of Shenyang Military Region

    Shenyang, Liaoning, China · Not yet recruiting

  • Liaoning Tumor Hospital & Institute

    Shenyang, Liaoning, China · Not yet recruiting

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China · Recruiting

  • the People'S Hospital

    Shenyang, Liaoning, China · Not yet recruiting

  • Tieling city Central Hospital

    Tieling, Liaoning, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.